Vistagen
@Vistagen
Followers
18K
Following
56
Statuses
5K
Vistagen ($VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry
South San Francisco
Joined September 2011
Last week, we initiated PALISADE-3, a pivotal Phase 3 trial of Fasedienol, targeting social anxiety disorder (SAD). With over 25 million Americans affected, our commitment to pioneering neuroscience drives us forward. Learn more here #PALISADE3 #Innovation
3
3
16
Vistagen will host a conference call and webcast on Thursday, February 13 at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. Register here: $VTGN
0
0
1
Vistagen today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of #neuropathicpain. Read more: $VTGN
2
5
15
Recent positive results from our Phase 2A study of PH284 demonstrated improvements to subjective feeling of hunger as compared to placebo and appeared safe and well-tolerated in cancer patient population. For more information: $VTGN
1
0
1
Vistagen recently announced positive results from the Phase 2A study of PH284, an investigational pherine nasal spray. PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal. $VTGN
0
0
1
Vistagen CEO Shawn Singh comments on the recent positive results from the exploratory Phase 2A study of PH284, an investigational pherine nasal spray: $VTGN
0
0
4
Vistagen today announced positive results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients. For more details: $VTGN
2
2
7
Our CEO, Shawn Singh, comments on the enrollment of the first subject in a repeat dose study of fasedienol for the acute treatment of social anxiety disorder (SAD). Read more: $VTGN
0
2
6
Vistagen has enrolled the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). For full details: $VTGN
2
2
7
As we wrap up an exciting 2024 at Vistagen, we want to wish everyone a holiday season and a New Year filled with peace, health, and happiness. Remember, your mental health matters— take time to rest, recharge, and focus on what brings you joy. Here's to a healthy and bright 2025!
0
0
2
While at @Nasdaq to ring the Closing Bell for #WorldMentalHealthDay alongside @MindUP, Shawn Singh sat down with Behind the Bell to discuss our commitment to pioneering neuroscience to transform treatment of mental health disorders. Watch here: $VTGN
1
0
2
Thank you to @NasdaqExchange and @MindUP for helping us highlight the importance of mental health care during this year's #WorldMentalHealthDay.
✨ Improve lives. That's what @Vistagen & @MindUP both do. 👏 Delighted that Shawn Singh, @Vistagen's CEO and @goldiehawn, Actress/Founder of @MindUP, joined us at @NasdaqExchange recently. Catch their Behind the Bell. ⬇️
0
1
1
A replay of Shawn Singh's fireside chat from the Stifel 2024 Healthcare Conference is now available. Watch here: $VTGN
0
0
4
Today, CEO Shawn Singh will participate in a fireside chat at the Stifel 2024 Healthcare Conference at 3:35 p.m. ET. Access the webcast here: $VTGN
0
0
2
This week, Vistagen was named as one of BioSpace’s Best Places to Work! This recognition reflects the commitment of our exceptional team, whose passion for innovation and dedication to transforming mental health care make Vistagen a truly special place to work.
0
2
3
Vistagen CEO Shawn Singh will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18 at 3:35 p.m. ET. A webcast will be accessible on the “Events” page in the “Investors” section of our website. For details: $VTGN
0
0
1
Vistagen management will present and host 1-on-1 meetings at the Stifel 2024 Healthcare Conference on November 18-19 in NYC. A webcast will be available on the “Events” page of our website. To schedule a meeting, contact your Stifel representative. $VTGN
0
0
2
We were honored to join @MindUP last month to celebrate #WorldMentalHealthDay at the @Nasdaq Closing Bell! We believe in the importance of empowering people with tools to manage mental health, and stay committed to amplifying #mentalhealthawareness year-round.
💡 "I created @MindUP because I wanted [children] to have a way to feel healthier and to have more tools to be able to manage their emotional construct." Hear more from Actress @GoldieHawn on why she founded MindUP to build greater emotional literacy and improve resilience.
0
0
0
RT @MindUP: A moment to remember! ✨A few weeks ago, we celebrated World Mental Health Day with our Founder @goldiehawn by ringing the bell…
0
2
0